Race-neutral Global Lung Function Initiative 2022 equations alter COPD trial eligibility in a northeast Asian COPD cohort.
Joon Young Choi, Hyun Woo Lee, Min Kwang Byun, Jeong-Woong Park, Eunjeong Son, Yun Su Sim, Bumhee Yang, Jin Hwa Lee, Kwang Ha Yoo, Yet Hong Khor
原始摘要（英文原文）· Original abstract
Adopting race-neutral GLI 2022 reclassified 12.9% of Korean COPD patients from trial-eligible to ineligible mild disease, and these reclassified patients demonstrated significantly lower risks of exacerbations and mortality https://bit.ly/4cG1OZt.